Discover
SRPT
Sarepta Therapeutics, Inc.
16.51
1 x 16.60
1 x 23.50
bid
ask
-
0.93
5.33%
2 @ 04:08 AM
16.60 +0.09 (0.55%)
| Ytd | -23.28% | |
| 1y | -22.96% |
16.41
day range
17.23
14.68
52 week range
24.68
| Open | 17.12 | Prev Close | 17.44 | Low | 16.41 | High | 17.23 | Mkt Cap | 1.74B |
| Vol | 3.68M | Avg Vol | 3.01M | EPS | -1.57 | P/E | N/A | Forward P/E | 6.88 |
| Beta | 0.38 | Short Ratio | 7.77 | Inst. Own | 104.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 19.11 | 200-d Avg | 19.00 | 1yr Est | 21.64 |
SRPT News
benzinga.com
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Per
benzinga.com
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’
Cramer called Sarepta controversial, praised Avery Dennison and Ciena, favored ING and Santander, an
benzinga.com
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT)
benzinga.com
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and low
benzinga.com
Sarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clini
Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically
benzinga.com
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudi
On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of